Fulgent Genetics (NASDAQ: FLGT) CFO gets equity awards, covers taxes

Rhea-AI Filing Summary

Fulgent Genetics CFO Paul Kim reported equity awards and related tax withholdings in company stock. On February 23–24, 2026, he acquired multiple common stock grants tied to time-based and performance-based restricted stock units that vested upon meeting performance milestones from awards granted in 2023, 2024, and 2025.

To satisfy tax withholding obligations triggered by these vestings, shares were withheld at prices around $23 per share rather than sold on the open market. A new restricted stock unit grant will vest over three years, with one-third vesting 12 months after March 1, 2026 and the remainder in quarterly installments, subject to continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Paul

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Treasurer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		F		661(1)	D	$23.01	327,485	D
Common Stock	02/24/2026		A		5,721(2)	A	$0	333,206	D
Common Stock	02/24/2026		A		14,926(3)	A	$0	348,132	D
Common Stock	02/24/2026		A		26,673(4)	A	$0	374,805	D
Common Stock	02/24/2026		F		3,241(5)	D	$23.09	371,564	D
Common Stock	02/24/2026		F		8,456(6)	D	$23.09	363,108	D
Common Stock	02/24/2026		F		15,095(7)	D	$23.09	348,013	D
Common Stock	02/24/2026		A		31,182(8)	A	$0	379,195	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.

2. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023.

3. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024.

4. Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025.

5. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023.

6. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024.

7. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025.

8. Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date.

	/s/ Paul Kim	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Fulgent Genetics (FLGT) CFO Paul Kim report in this Form 4?

CFO Paul Kim reported multiple equity transactions involving Fulgent Genetics common stock. He received stock from vesting restricted stock units and new awards, and had shares withheld to cover tax obligations arising from those vestings rather than executing open-market sales of his holdings.

Were the Fulgent Genetics (FLGT) Form 4 transactions open-market stock sales?

No, the Form 4 does not show open-market sales. Dispositions are coded as tax-withholding transactions, where shares were withheld to pay exercise price or tax liabilities triggered by restricted stock unit vesting, rather than discretionary sales of shares into the public market.

What types of awards did the Fulgent Genetics (FLGT) CFO receive?

The CFO received common stock tied to performance-based restricted stock units granted in 2023, 2024, and 2025 that vested upon achievement of performance milestones. He also received new restricted stock units that vest over three years starting 12 months after March 1, 2026, contingent on continued service.

How do the new restricted stock units for Fulgent Genetics (FLGT) CFO vest?

The new restricted stock units vest over three years. One-third vests 12 months after March 1, 2026, and the remaining two-thirds vest in equal installments at the end of every three-month period over the following 24 months, subject to continued employment with the issuer.

Why were Fulgent Genetics (FLGT) shares withheld from CFO Paul Kim?

Shares were withheld to satisfy tax withholding obligations from vesting restricted stock units. Instead of paying taxes in cash, a portion of vested shares was retained by the issuer at prices around $23 per share, consistent with standard equity compensation tax-settlement practices.